Urinary tract infection (UTI) is a common infection in communities. The use of an initial appropriate antibiotic usually improves a patient\'s prognosis. Earlier studies have reported that the indiscriminate use of antibiotics for treating UTIs resulted in a lower cure rate, longer hospital stay, higher relapse rate, and accelerated development of antibiotic resistance.[@B1][@B2][@B3] In previous studies in Korea, in 2010, the *Escherichia coli* susceptibility to ciprofloxacin had decreased to less than 80% while that to cefotaxime remained high.[@B4][@B5] Hence, cefotaxime was used to treat community-onset UTIs and the susceptibility to cefotaxime may be decreased. Moreover, there has been an increase in the incidence of extended-spectrum β-lactamase (ESBL)-producing *E. coli* in community-onset UTIs.[@B6][@B7] Residence in a healthcare facility is an independent risk factor of ESBL-producing *E. coli* infections.[@B8] The clinical features and the antibiotic susceptibility pattern of the causative pathogens differ from patients residing in a healthcare facility and those living at home.[@B9] Therefore, it is necessary to classify the community-onset UTI into simple community-acquired UTI (CA-UTI) and healthcare-associated community acquired UTI (HCA-UTI) when investigating the antibiotic susceptibility pattern of *E. coli*.

In this study, we evaluated the antimicrobial susceptibility pattern of *E. coli* in community-onset UTI, which were divided into CA-UTI and HCA-UTI between 2008 and 2017. This study was approved by the Institutional Review Board (IRB) of Wonkwang University Hospital (Board approval No. WKUHIRB 2018-11-013).

The patients who visited the emergency room of Wonkwang University Hospital with community-onset UTI caused by *E. coli* between January 2008 and December 2017 were selected for the study. We retrospectively reviewed the patients\' medical records to exclude subjects with asymptomatic bacteriuria, patients who had been transferred from other acute care hospitals, and those who relapsed within 14 days of completing therapy. We used 12 antimicrobial agents (ampicillin, cefazolin, cefotaxime, cefepime, aztreonam, gentamicin, piperacillin-tazobactam \[PIP-TAZ\], ciprofloxacin, TMP-SMX, amikacin, ertapenem, and imipenem) for the susceptibility test. The antibiotic susceptibility test was performed using a VITEK 2 system (bioMérieux, Hazelwood, MO, USA) according to the guidelines prescribed by the Clinical and Laboratory Standards Institute (CLSI).[@B10][@B11][@B12] The CLSI breakpoints of 2010 and 2014 were applied in May 2012 and May 2014, respectively.

Asymptomatic bacteriuria was defined as the presence of bacteria in the properly collected urine sample of patients who had no local or systemic signs and symptoms, such as fever, chills, malaise, acute altered mental status, flank pain, back pain, or costo-vertebral angle pain or tenderness. Community-onset UTI was defined as the infection that was diagnosed within 48 hours of admission into the hospital. The patients with community-onset UTI were further grouped into the CA-UTI and HCA-UTI groups. Patients in the HCA-UTI group were defined using the modified criteria of Friedman et al.[@B9]: 1) hospitalized in an acute-care hospital for 2 or more days within 90 days, 2) attending a hospital for hemodialysis or receiving intravenous chemotherapy within 30 days, 3) residing in a nursing home or long-term care facility, 4) having a long-term indwelling urethral catheter or suprapubic cystostomy.

We compared the annual antibiotic susceptibility of *E. coli* using χ^2^ test. The data were considered statistically significant when the *P* value was less than 0.05 (two-sided). All statistical analyses were performed using SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA).

In this study, we included 1,496 patients (aged \> 18 years) with community onset UTI caused by *E. coli*. There was no previous history of UTI in 96% of the patients. The proportion of patients who had been hospitalized for at least 48 hours was 73.2%. The mean age of the patients was 65.5 ± 17.8 years and 85.6% of the patients were women. 95.7% of the patients were diagnosed with pyelonephritis, and 4.3% of the patients were diagnosed with cystitis. We classified 31% of the patients into the HCA-UTI group. The proportion of patients with complicated UTI was 24.4%, and 24.5% of the patients had a long-term indwelling urethral catheter or suprapubic cystostomy.

The susceptibility of *E. coli* to cefazolin, cefotaxime, cefepime, aztreonam, PIP-TAZ, gentamicin, and ciprofloxacin decreased significantly with each year during the study period. The susceptibility of *E. coli* to cefotaxime declined continuously during the study period and was less than 70% in 2017. The susceptibility *E. coli* to cefepime was more than 90% until 2013 but rapidly decreased to less than 80% in 2015. Similarly, the susceptibility of *E. coli* to aztreonam was less than 80% in 2014. *E. coli* was highly susceptible to PIP-TAZ until 2015, but it decreased to about 87% in 2016. The susceptibility to TMP-SMX was above 60% during the study period with minimal change. The susceptibility to ciprofloxacin decreased to less than 60% in 2014. The susceptibility to TMP-SMX was higher than that to ciprofloxacin in 2010. The susceptibility to amikacin and imipenem was very high during the study period. The incidence of ESBL-producing *E. coli* steadily increased from 4.5% to 33.1% ([Table 1](#T1){ref-type="table"}).

The susceptibility to most antibiotics, except amikacin and imipenem, was different between the CA-UTI and HCA-UTI groups. The susceptibility to cefotaxime in the CA-UTI group was around 90% until 2015 (88% in 2015). However, the susceptibility to cefotaxime of this group decreased to less than 80% (79.3% in 2017). The susceptibility to cefotaxime in HCA-UTI group was 50% in 2012. The susceptibility to cefepime in the CA-UTI group was 88.8% in 2017. However, the susceptibility to cefepime in the HCA-UTI group remarkably decreased to below 80% in 2013 and dropped to less than 60% in 2015. The susceptibility PIP-TAZ in the CA-UTI group was 90.5% in 2017, but that in the HCA-UTI group dropped to below 90% in 2015, and the lowest susceptibility was observed in 2016 (76.7%). The susceptibility to aztreonam in the CA-UTI group was 94.8% in 2016 but decreased to 82.8% in 2017. The susceptibility to aztreonam in the HCA-UTI group significantly decreased to below 70% in 2012 and the lowest susceptibility was observed in 2015 (53.7%). The susceptibility to ciprofloxacin in the CA-UTI group decreased to 70.7% in 2017. However, the susceptibility to ciprofloxacin in the HCA-UTI group decreased to less than 40% in 2013, and the lowest susceptibility was observed in 2016 (28.9%). The susceptibility to TMP-SMX in the CA-UTI and in HCA-UTI groups was 67.2% and 63.1%, respectively in 2017. The incidence of ESBL-producing *E. coli* markedly significantly increased from 0.0% to 23.3% in the CA-UTI group (*P* \< 0.001). In the HCA-UTI group, the incidence of ESBL-producing *E. coli* began to exceed 50% in 2012 ([Fig. 1](#F1){ref-type="fig"}).

During the study period, the susceptibility of *E. coli* to most antibiotics continued to decrease while the incidence of ESBL-producing *E. coli* increased markedly. The susceptibility to most antibiotics was different between the CA-UTI and HCA-UTI groups. In this study, we observed that the susceptibility to cefotaxime markedly decreased in patients with community-onset UTI. The production of ESBL is an important mechanism for developing cefotaxime resistance in *E. coli*.[@B13] In this study, the incidence of ESBL-producing *E. coli* increased sharply after 2015. Concurrently, a decreased susceptibility to cefotaxime was observed after 2015. As reported in earlier studies,[@B6][@B7] we observed that the incidence of ESBL-producing *E. coli* in the CA-UTI group was around 10% until 2016. However, the incidence rapidly increased, nearly doubling by the year 2017 (from 12.7% to 23.3%). Hence, it is necessary to constantly monitor the rapid incidence of ESBL-producing *E. coli*. Carbapenems are generally considered the drug of choice for treating of ESBL-producing *E. coli* infection.[@B14][@B15] Ciprofloxacin or TMP-SMX can be used for treating UTI caused by ESBL-producing *E. coli*.[@B16] However, in this study, most ESBL-producing *E. coli* had co-resistance to ciprofloxacin (79.5%, 245/308) and TMP-SMX (53.9%, 166/308). PIP-TAZ can be as effective as carbapenem in treating UTI caused by ESBL-producing *E. coli*.[@B17][@B18] The susceptibility to PIP-TAZ remained high in the CA-UTI group during this study period, but in the HCA-UTI group decreased to 80% in 2016. The susceptibility to ciprofloxacin continuously decreased to 70% in the CA-UTI group and was less than 40% in the HCA-UTI group. However, there was very little change in the susceptibility to TMP-SMX during the study period and was similar that to ciprofloxacin in 2010.

This study has several limitations. During this study, the twice changed CLSI guidelines were applied to the susceptibility test, and the breakpoints for *E. coli* were lowered in May 2012. This was a retrospective observational study performed at a single university hospital. This study included a high proportion of patients who had severe UTI and needed hospitalization, which may limit the generalization of our results to cystitis or UTI in outpatient clinics. This study demonstrated the change in antibiotic susceptibility pattern in a 10-year study period. Our study also classified the patients based on CA-UTI and HCA-UTI. The results of this study may aid in selecting the appropriate early antibiotics for treating community-onset UTIs.
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###### Antibiotic susceptibility and incidence of ESBL-producing *Escherichia coli* from 2008 to 2017
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  Susceptibility, % (Total = 1,496)                           2008 (n = 88)   2009 (n = 90)   2010 (n = 94)   2011 (n = 124)   2012 (n = 164)   2013 (n = 195)   2014 (n = 190)   2015 (n = 146)   2016 (n = 224)   2017 (n = 181)   *P* value   
  ----------------------------------------------------------- --------------- --------------- --------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------- ----------
  Percentage of patients with susceptibility to antibiotics                                                                                                                                                                                      
                                                              Ampicillin      37.5            35.6            41.5             34.7             32.9             36.1             32.8             34.2             27.2             35.4        0.508
                                                              PIP-TAZ         98.9            96.7            96.8             NA               96.2             91.8             94.7             93.8             87.9             87.3        \< 0.001
                                                              Cefazolin       89.8            76.7            NA               64.5             70.7             79.5             74.2             65.8             62.5             62.7        \< 0.001
                                                              Cefotaxime      95.5            91.1            87.1             85.5             81.7             81.5             78.4             69.7             67.9             68.0        \< 0.001
                                                              Cefepime        95.5            93.3            95.7             95.2             94.5             92.8             87.8             78.8             77.7             78.5        \< 0.001
                                                              Aztreonam       97.7            92.2            92.5             94.4             89.0             87.2             79.5             79.5             78.6             76.2        \< 0.001
                                                              Imipenem        98.9            100.0           100.0            100.0            100.0            100.0            100.0            100.0            100.0            100.0       
                                                              Ertapenem       NA              NA              NA               NA               NA               99.5             100.0            99.3             99.5             100.0       
                                                              Gentamicin      79.5            75.6            74.5             77.4             75.0             75.4             69.2             69.2             63.4             65.7        0.018
                                                              Amikacin        100.0           98.9            97.9             97.6             98.8             100.0            99.3             99.3             99.1             98.9        
                                                              TMP-SMX         68.2            63.3            72.3             69.4             68.9             70.8             62.3             62.3             62.5             65.7        0.568
                                                              Ciprofloxacin   79.5            71.1            66.0             67.7             71.3             64.6             58.9             58.9             51.8             58.6        \< 0.001
                                                              ESBL            4.5             10.0            13.8             12.9             18.9             15.9             18.9             28.1             29.9             33.1        \< 0.001

ESBL = extended spectrum β-lactamase, *E. coli* = *Escherichia coli*, NA = not applicable, PIP-TAZ = piperacillin-tazobactam, TMP-SMX = trimethoprim-sulfamethoxazole.
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